{"id":"ic51-japanese-encephalitis","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IC51 contains inactivated Japanese encephalitis virus particles that trigger both humoral (antibody) and cell-mediated immune responses. The vaccine is designed to provide protection against infection by Japanese encephalitis virus, a flavivirus transmitted by mosquitoes in Asia and the Western Pacific region. By priming the immune system, the vaccine aims to prevent symptomatic infection and severe disease.","oneSentence":"IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:27.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in adults and children"}]},"trialDetails":[{"nctId":"NCT00594958","phase":"PHASE3","title":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2006-09","conditions":"Japanese Encephalitis","enrollment":639},{"nctId":"NCT00605085","phase":"PHASE3","title":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":2675},{"nctId":"NCT00604708","phase":"PHASE3","title":"Immunogenicity Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":867},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT01047839","phase":"PHASE3","title":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-01","conditions":"Encephalitis","enrollment":100},{"nctId":"NCT01246479","phase":"PHASE3","title":"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-10","conditions":"Japanese Encephalitis","enrollment":23},{"nctId":"NCT00776230","phase":"PHASE3","title":"Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2008-09","conditions":"Japanese Encephalitis","enrollment":304},{"nctId":"NCT01296360","phase":"PHASE3","title":"Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-12","conditions":"Japanese Encephalitis","enrollment":300},{"nctId":"NCT00596102","phase":"","title":"Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":3258},{"nctId":"NCT00595309","phase":"PHASE3","title":"Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2007-12","conditions":"Japanese Encephalitis","enrollment":198},{"nctId":"NCT00595465","phase":"PHASE3","title":"Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2007-12","conditions":"Japanese Encephalitis","enrollment":389},{"nctId":"NCT00596271","phase":"PHASE3","title":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":192},{"nctId":"NCT00595790","phase":"PHASE3","title":"Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":374},{"nctId":"NCT00595270","phase":"PHASE3","title":"Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":349},{"nctId":"NCT01158599","phase":"PHASE4","title":"This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-06","conditions":"Japanese Encephalitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IC51 Japanese Encephalitis","genericName":"IC51 Japanese Encephalitis","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}